OMass Therapeutics Ltd, a developer of small molecule therapeutics in endocrinology and immunology, has appointed Carol A. Schafer as non-executive director and chair of the audit committee. Ms Schafer brings more than 25 years of experience in healthcare investment banking and biotech board membership. She currently serves on the boards of Insmed, Immunome, Kura Oncology and Repare Therapeutics, all listed on Nasdaq, US. Ms Schafer holds an MBA from New York University’s Stern School of Business, US and has held senior roles at Wells Fargo Securities and J.P. Morgan.
Copyright 2025 Evernow Publishing Ltd